肝胆肿瘤新辅助治疗疗效预测因子的探索与评价  

Exploration and evaluation of predictors of efficacy in neoadjuvant therapy for hepatobiliary neoplasms

作　　者：高强[1] 刘羽鸣 GAO Qiang;LIU Yu-ming(Zhongshan Hospital Affiliated to Fudan University,Fudan University Liver Cancer Institute,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院、复旦大学肝癌研究所,上海200032

出　　处：《中国实用外科杂志》2023年第3期260-266,共7页Chinese Journal of Practical Surgery

基　　金：国家自然科学基金(No.81961128025)。

摘　　要：肝胆肿瘤因发病率高、复发率高、死亡率高,严重威胁着我国人民的健康,病因预防、早筛早诊、药物治疗和综合治疗的进步有望改变这一现状。其中,靶向免疫药物的新辅助治疗作为提高手术治疗疗效的重要手段受到了广泛的关注,但也因受有效率有限和副反应的发生限制了其推广和应用。因此,鉴定有效的生物标记物筛选出潜在获益人群、降低不良反应的发生率迫在眉睫。肝胆肿瘤的预测新辅助靶向联合免疫治疗(靶免治疗)疗效的生物标记物研究尚处起步阶段,而在其他癌种和进展期肝胆肿瘤中已有部分研究成果。整合多尺度的标记物是肝胆肿瘤新辅助疗效预测的未来方向。Hepatobiliary cancers seriously threaten the health of our people due to their high morbidity,recurrence rate and mortality.Advances in primary prevention,early screening and early diagnosis,drug therapy,and systemic treatment are expected to change this situation.Neoadjuvant targeted therapy and immunotherapy have received widespread attention as one of the promising ways to improve the efficacy of surgical treatment.However,its promotion and application are limited due to unsatisfactory response efficiency and the occurrence of adverse events.Therefore,it is urgent to find effective biomarkers to screen out potential benefit groups and reduce the incidence of adverse events. In hepatobiliarycancers, the research on biomarkers to predict the efficacy ofneoadjuvant target immunotherapy is still in its infancy, whilesome research results have been obtained in other types ofcancers and advanced hepatobiliary cancers. Integrating multiscalemarkers is a future direction for the prediction ofneoadjuvant efficacy in hepatobiliary tumors.

关 键 词：肝胆肿瘤 新辅助治疗 免疫治疗 靶向治疗 疗效标记物 

分 类 号：R6[医药卫生—外科学]